Oncotarget

Research Papers:

AG488 as a therapy against gliomas

Jadith Ziegler, Anja Bastian, Megan Lerner, Lora Bailey-Downs, Debra Saunders, Nataliya Smith, Jake Sutton, James D. Battiste, Michael A. Ihnat, Aleem Gangjee and Rheal A. Towner _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:71833-71844. https://doi.org/10.18632/oncotarget.18284

Metrics: PDF 519 views  |   HTML 929 views  |   ?  


Abstract

Jadith Ziegler1,2, Anja Bastian3, Megan Lerner4, Lora Bailey-Downs3, Debra Saunders1, Nataliya Smith1, Jake Sutton1, James D. Battiste5, Michael A. Ihnat3, Aleem Gangjee6 and Rheal A. Towner1,2,3,5

1Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

2Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

3Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

4Department of Surgery Research Laboratory, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

5Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

6Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA, USA

Correspondence to:

Rheal A. Towner, email: Rheal-Towner@omrf.org

Keywords: gliomas, magnetic resonance imaging (MRI), in vivo, anti-cancer therapy, angiogenesis

Received: February 13, 2017    Accepted: May 05, 2017    Published: May 30, 2017

ABSTRACT

High-grade gliomas such as glioblastomas (GBM) present a deadly prognosis following diagnosis and very few effective treatment options. Here, we investigate if the small molecule AG488 can be an effective therapy against GBM with both anti-angiogenic as well as an anti-microtubule inhibiting modalities, using a human G55 glioma xenograft model in nude mice. From in vitro studies, we report that AG488 incubation reduced cell viability in G55 and HMEC-1 cells more so than TMZ treatment, and AG488 treatment also decreased cell viability in normal astrocytes, but not as much as for G55 cells (p<0.0001). In vivo investigations indicated that AG488 therapy helped reduce tumor volumes (p<0.0001), prolong survival (p<0.01), increase tumor perfusion (p<0.01), and decrease microvessel density (MVD) (p<0.05), compared to untreated mice or mice treated with non-specific IgG, in the G55 xenograft model. Additionally, AG488 did not induce apoptosis in normal mouse brain tissue. Animal survival and tumor volume changes for AG488 were comparable to TMZ or anti-VEGF therapies, however AG488 was found to be more effective in decreasing tumor-related vascularity (perfusion and MVD). AG488 is a potential novel therapy against high-grade gliomas.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18284